RECRUITING

Automating Delirium Severity in the ICU

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to develop a passive digital marker (PDM) for delirium severity and examine its performance in comparison to validated delirium severity tools in ICU patients \>50 years of age. The main questions it aims to answer are: * Is the trained convolutional neural network able to reliably measure delirium severity. * Is the Passive Digital Marker able to accurately measure delirium severity * Is the Passive Digital Marker acceptable and usable by frontline ICU nurse clinicians, patients, and their identified proxies (i.e., caregivers). Participants will: * Study participation involves a video camera recording you 24 hours per day while you are a patient in the Intensive Care Unit (ICU). * Study staff will visit you 4 times each day you are in the ICU. You will be asked questions each time they visit to train the digital marker and see differences between assessments and camera data.

Official Title

Harnessing the Power of Technology to Transform Delirium Severity Measurement in the ICU

Quick Facts

Study Start:2023-01-15
Study Completion:2026-12-18
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06172491

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Not specified
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Estimated length of stay \>24 hours in ICU; and
  2. * Are not admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal.
  1. * Admitted for acute alcohol intoxication, drug (prescribed or illicit) overdose or withdrawal.
  2. * Admitted for acute neuronal injury
  3. * Unable to communicate with research team due to sensory deficits (aphasic, blind, deaf) or language (does not speak English)

Contacts and Locations

Study Contact

Heidi Lindroth, PH.D. R.N.
CONTACT
507-284-3662
lindroth.heidi@mayo.edu
Kathleen R Leistikow
CONTACT
1-507-422-3994
leistikow.kathleen@mayo.edu

Study Locations (Sites)

Mayo Clinic
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-15
Study Completion Date2026-12-18

Study Record Updates

Study Start Date2023-01-15
Study Completion Date2026-12-18

Terms related to this study

Keywords Provided by Researchers

  • Delirium
  • Severity
  • Digital marker
  • Computer Vision
  • Artificial Intelligence

Additional Relevant MeSH Terms

  • Intensive Care Unit Delirium
  • Encephalopathy
  • Delirium